Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Terlivaz

(Terlipressin acetate)

Small molecule

0

Indications

1

Total Trials

0

Active Trials

0

Competitors

1

FDA Application

NDA/BLA/ANDA regulatory filings

Clinical

Trials by Indication[1]

Portal Hypertension1 trial

An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension

Completed· Novartis logo

Novartis·Phase 2·NCT01640964·47 enrolled

Regulatory

FDA Approval Timeline[3]

Sep 14, 2022

TERLIVAZ

NDA NDA022231

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Terlipressin acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Terlipressin acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
OpenFDA — FDA approval records (NDA NDA022231). U.S. Food & Drug Administration.
[4]
SEC EDGAR — Mallinckrodt company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: MMallinckrodt

Related News